MedPath

Phase II study of prophylactic oral administration of diltiazem for atrial fibrillation after lung resectio

Phase 2
Recruiting
Conditions
atrial fibrillation after lung resection
Registration Number
JPRN-UMIN000001691
Lead Sponsor
Department of Surgical Oncology, Hokkaido University Graduate School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
124
Inclusion Criteria

Not provided

Exclusion Criteria

unstable angina pectoris, myocardial infarction or heart failure with in 3 months uncontrolled diabetes or hypertension active infection gastrointestinal bleeding diarrhea ileus chronic Af already taking diltiazem or other calcium blocker AV block more than 2nd degree sick sinus syndrome past history of severe allergy uncontrolled pleural effusion, ascites or pericardial fluid in pregnancy

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Incidence of atrial fibrillation after lung resection
Secondary Outcome Measures
NameTimeMethod
Degree and frequency of adverse event (hypotension, bradycardia, etc.)
© Copyright 2025. All Rights Reserved by MedPath